Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,520 across all filing types
Latest filing 2023-09-15 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF 2023 INTERIM REPORT
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated 18 September 2023 from CSPC Pharmaceutical Group Limited informing non-registered shareholders about the publication of the 2023 Interim Report. It provides links to the report on the company's and the stock exchange's websites and includes a request form for shareholders to receive printed copies of the interim report and future corporate communications. The document does not contain the actual interim report or any financial data but merely announces the availability of the report and facilitates shareholder access to it. According to the 'MENU VS MEAL' rule, such a notification letter is classified as a Report Publication Announcement (RPA) rather than the Interim Report (IR) itself.
2023-09-15 English
INTERIM REPORT 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT 2023' and contains detailed financial statements such as condensed consolidated income statement, statement of comprehensive income, statement of financial position, statement of changes in equity, and statement of cash flows. It also includes a Management Discussion and Analysis section, financial highlights for the six months ended 30 June 2023, and detailed business review and operational commentary. The presence of actual financial data and comprehensive analysis for a period shorter than a full fiscal year (half-year) clearly indicates this is an interim or quarterly report. The length of the document (15,000 characters) and the detailed content confirm it is the report itself, not just an announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-09-15 English
APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the appointment of an independent financial adviser related to a takeover transaction and a whitewash waiver. It references a previous announcement and states that the letter of advice will be included in a forthcoming circular to shareholders. The document is short (2736 characters) and serves as a notification rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. It is clearly an announcement related to a corporate transaction and advisory appointment, fitting best under the category of a Regulatory Filing (RNS) as it does not fit other more specific categories like M&A filings or capital updates directly, and is not a full report or presentation.
2023-09-12 English
(REVISED) VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR NARLUMOSBART FOR INJECTION (JMT103) APPROVED BY THE NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a biologic license application (BLA) for a new drug by the National Medical Products Administration (NMPA) of China. It is an announcement of a regulatory milestone related to product approval, not a financial report, earnings release, or management discussion. The document is relatively short (3486 characters) and serves as a public announcement of a significant event rather than a detailed report or filing. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-06 English
VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR NARLUMOSBART FOR INJECTION (JMT103) APPROVED BY THE NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a biologic license application (BLA) for a new drug by the National Medical Products Administration (NMPA) of China. It is an announcement of a regulatory milestone related to product approval, not a financial report, earnings release, or management discussion. The document is relatively short (3489 characters) and serves as a formal announcement rather than a detailed report or presentation. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-06 English
GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME AND APPLICATION FOR WHITEWASH WAIVER
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conditional grant of share options under a share option scheme and an application for a whitewash waiver. It details the number of share options granted, exercise price, vesting conditions, and the requirement for shareholder approval at an Extraordinary General Meeting (EGM). It also discusses the involvement of an Independent Board Committee and an independent financial adviser. The document is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about share option grants and related shareholder meeting arrangements. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best under Capital/Financing Update (CAP) as it relates to share option grants and potential issuance of new shares, which affect the company's capital structure.
2023-09-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.